- Home
- PINE vs LUNG Comparison
PINE vs LUNG Comparison
Compare PINE & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINE
- LUNG
- Stock Information
- Founded
- PINE 2019
- LUNG 1995
- Country
- PINE United States
- LUNG United States
- Employees
- PINE N/A
- LUNG N/A
- Industry
- PINE Real Estate Investment Trusts
- LUNG Industrial Specialties
- Sector
- PINE Real Estate
- LUNG Health Care
- Exchange
- PINE Nasdaq
- LUNG Nasdaq
- Market Cap
- PINE 239.5M
- LUNG 251.5M
- IPO Year
- PINE 2019
- LUNG 2020
- Fundamental
- Price
- PINE $16.44
- LUNG $6.23
- Analyst Decision
- PINE Strong Buy
- LUNG Buy
- Analyst Count
- PINE 9
- LUNG 6
- Target Price
- PINE $19.39
- LUNG $11.92
- AVG Volume (30 Days)
- PINE 103.3K
- LUNG 242.6K
- Earning Date
- PINE 02-06-2025
- LUNG 02-19-2025
- Dividend Yield
- PINE 6.77%
- LUNG N/A
- EPS Growth
- PINE N/A
- LUNG N/A
- EPS
- PINE 0.23
- LUNG N/A
- Revenue
- PINE $50,017,000.00
- LUNG $79,302,000.00
- Revenue This Year
- PINE N/A
- LUNG $22.26
- Revenue Next Year
- PINE $6.76
- LUNG $18.72
- P/E Ratio
- PINE $71.61
- LUNG N/A
- Revenue Growth
- PINE 9.55
- LUNG 22.34
- 52 Week Low
- PINE $14.33
- LUNG $5.46
- 52 Week High
- PINE $19.42
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- PINE 31.65
- LUNG 41.37
- Support Level
- PINE $17.04
- LUNG $5.72
- Resistance Level
- PINE $17.37
- LUNG $6.28
- Average True Range (ATR)
- PINE 0.35
- LUNG 0.40
- MACD
- PINE -0.13
- LUNG -0.03
- Stochastic Oscillator
- PINE 18.76
- LUNG 19.85
About PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate company. It owns and operates a portfolio of single-tenant commercial properties. The company's portfolio is comprised of single-tenant retail and office properties located in or in close proximity to MSAs, growth markets and other markets in the United States. Their portfolio consists of One thirty eight net leased properties located in Hundred and four markets in thirty five states. The majority of the firm's revenue includes rental revenue derived from the ownership and leasing of property.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.